Your browser doesn't support javascript.
loading
Pharmacokinetic Markers of Clinical Outcomes in Severe Mental Illness: A Systematic Review.
Paribello, Pasquale; Manchia, Mirko; Pinna, Federica; Isayeva, Ulker; Squassina, Alessio; Pisanu, Claudia; Balderi, Lorenzo; Contu, Martina; Pinna, Marco; Carpiniello, Bernardo.
Afiliación
  • Paribello P; Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy.
  • Manchia M; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, 09124 Cagliari, Italy.
  • Pinna F; Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy.
  • Isayeva U; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, 09124 Cagliari, Italy.
  • Squassina A; Department of Pharmacology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
  • Pisanu C; Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy.
  • Balderi L; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, 09124 Cagliari, Italy.
  • Contu M; Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy.
  • Pinna M; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, 09124 Cagliari, Italy.
  • Carpiniello B; Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Science, University of Cagliari, 09042 Cagliari, Italy.
Int J Mol Sci ; 24(5)2023 Mar 01.
Article en En | MEDLINE | ID: mdl-36902205
The term severe mental illness (SMI) encompasses those psychiatric disorders exerting the highest clinical burden and socio-economic impact on the affected individuals and their communities. Pharmacogenomic (PGx) approaches hold great promise in personalizing treatment selection and clinical outcomes, possibly reducing the burden of SMI. Here, we sought to review the literature in the field, focusing on PGx testing and particularly on pharmacokinetic markers. We performed a systematic review on PUBMED/Medline, Web of Science, and Scopus. The last search was performed on the 17 September 2022, and further augmented with a comprehensive pearl-growing strategy. In total, 1979 records were screened, and after duplicate removal, 587 unique records were screened by at least 2 independent reviewers. Ultimately, forty-two articles were included in the qualitative analysis, eleven randomized controlled trials and thirty-one nonrandomized studies. The observed lack of standardization in PGx tests, population selection, and tested outcomes limit the overall interpretation of the available evidence. A growing body of evidence suggests that PGx testing might be cost-effective in specific settings and may modestly improve clinical outcomes. More efforts need to be directed toward improving PGx standardization, knowledge for all stakeholders, and clinical practice guidelines for screening recommendations.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Mentales Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research / Systematic_reviews Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Mentales Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research / Systematic_reviews Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza